ANNA DUMAS: Open Payments
NPI 1831408350 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 48 payments from 19 companies in 2025. Trend: 2023 $1,208 · 2024 $717 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $187 |
| AstraZeneca Pharmaceuticals LP | 6 | $162 |
| Corcept Therapeutics | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $48 |
| Astellas Pharma US Inc | 2 | $45 |
| Verona Pharma, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Amgen Inc. | 2 | $31 |
Products named: Korlym, BREZTRI, QULIPTA, VRAYLAR, REXULTI, FANAPT, UBRELVY, JOURNAVX.
Industry payments across AL — which companies pay providers there.
